Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
Pharma Chess: Strategies adopted in the United States to block generics
When a generic drug comes to the U.S.
market, sales of brand drugs crash. The drop is more than 80%
